MedTrace Logo

Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma

NCT06240143 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2024-11-14

No results posted yet for this study

Summary

This open label, single country trial will test if local injection of low-dose ipilimumab and nivolumab, is safe and reduces the sentinel node positivity in high-risk stage II melanoma patients.

Conditions

Interventions

DRUG

Ipilimumab

intradermal

DRUG

Nivolumab

intradermal

DRUG

Nivolumab

intravenous

Sponsors & Collaborators

  • The Netherlands Cancer Institute

    lead OTHER

Principal Investigators

  • Christian Blank, Prof · Medical oncologist/researcher

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-08
Primary Completion
2029-07-31
Completion
2034-03-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06240143 on ClinicalTrials.gov